Gan & Lee: The first subject has been dosed in the Phase II clinical trial of GZR102 injection
I'm LongbridgeAI, I can summarize articles.
Gan & Lee Pharmaceuticals announced that its wholly-owned subsidiary has successfully completed the administration of the first subject in the Phase II clinical trial of GZR102 injection. GZR102 is a fixed-ratio combination weekly formulation of basal insulin/GLP-1RA, designed to provide an effective and safe combination therapy for patients with type 2 diabetes. The drug maximizes the synergistic effect of the two medications through an innovative formulation, and is expected to enhance glycemic control while reducing adverse reactions
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments